# Oncimmune Holdings plc Excellent progress and well placed

- Link: https://www.directorstalkinterviews.com/oncimmune-holdings-plc-excellent-progress-well-placed/412738516
- Published: 2017-10-20T07:11:13+01:00
- Author: Giles Arbor

**Oncimmune Holdings plc** (LON:ONC), a leading early cancer detection company developing
and commercialising its proprietary EarlyCDT® platform technology, today announced
its full year results for the year ended 31 May 2017.

**Financial Highlights**

· Revenues for the year were £0.22m (2016: £0.43m).

· Operating costs before share based charges and exceptional items were £4.88 million(
2016: £3.8m).

· Net loss for the year was £5.0m (2016: £4.6m) before any exceptional items.

· Cash balance at the year-end was £5.08m (2016: £10.2m). At the end of September,
the cash balance was £6.5m reflecting monies raised in September 2017.

· £5.0m raised by means of a conditional placing with new and existing investors.
Of this, £1.0m remains outstanding and conditional on receipt from HM Revenues &
Customs of confirmation that this investment will be a qualifying holding for the
purposes of Part 6 of the Income Tax Act 2007.

**Corporate & operational highlights (including post-period end)**

· EarlyCDT®-Lung commercial progress

o CE Mark for the EarlyCDT®-Lung kit received in May 2017, with first commercial
batches expected to be shipped by no later than the end of October 2017.

o First distribution agreements signed by Oncimmune’s Asian (including Israel) business
which provide minimum payment guarantees of over £6.1m over the next five years.

o First distribution agreements for the EarlyCDT®-Lung kit in Europe for Denmark,
Norway, Sweden and Poland with an aggregate minimum sales commitment of approximately
£1.4m over the next four years.

o In September 2017, the Company entered into a four-month preliminary distribution
partnership with a major US pulmonary sales force for the use of EarlyCDT®-Lung 
in assessing indeterminate lung nodules which, if successful, should lead to a distribution
agreement for U.S. pulmonologists.

· R&D and Trials

o Foundations for the commercial panel for the EarlyCDT®-Liver test have been laid
with validation due for completion by the end of 2017 and commercial sales on track
to begin in H1 2018. EarlyCDT®-Ovarian is expected thereafter.

o NHS Lung Cancer Screening Trial is fully recruited: 12,210 patients with final
study results in 2019; latest interim data presented at the European 27th International
Congress of the European Respiratory Society (ERS) in Milan in September 2017.

· Personalised Medicine & Companion Diagnostics

o Presentation of data on the use of Oncimmune’s autoantibody technology to successfully
predict disease recurrence in subjects undergoing immunotherapy with Scancell Holding
plc’s SCIB1 immunotherapy for malignant melanoma.

o Autoantibody “fingerprint” technology development progressing well with data expected
to be presented in Q4 2017.

> **Geoffrey Hamilton-Fairley, CEO, of Oncimmune Holdings plc said:** “We continue
> to make excellent progress towards our goal of building a pioneering early cancer
> detection platform which can generate revenues across multiple products, regions
> and with different partners. Gaining CE mark for the EarlyCDT®-Lung kit was a 
> key milestone and we have already seen its impact with partnerships in Asia and
> Europe. With a strong team in place, a fundraising completed and our R&D progressing
> well the board is increasingly confident that the Company is well placed to execute
> that plan and deliver value in the medium and long term.”

Share on:
